Joseph Lyssikatos
Founder at ENLIVEN THERAPEUTICS, INC.
Net worth: 25 M $ as of 2024-05-30
Profile
Dr. Joseph P.
Lyssikatos is a Chief Scientific Officer at Enliven Therapeutics, Inc. and a Director & Chief Scientific Officer at Enliven Therapeutics, Inc. /US/.
He is on the Board of Directors at Enliven Therapeutics, Inc. /US/.
Dr. Lyssikatos was previously employed as an Executive Director by AbbVie, Inc. and a Senior Director by Array BioPharma, Inc. He received his undergraduate degree from The College of William & Mary and a doctorate degree from the University of California, Berkeley.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-05-28 | 1,117,035 ( 2.37% ) | 25 M $ | 2024-05-30 |
Joseph Lyssikatos active positions
| Companies | Position | Start |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Founder | 2019-05-31 |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Founder | - |
Former positions of Joseph Lyssikatos
| Companies | Position | End |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Director/Board Member | - |
| ABBVIE INC. | Director/Board Member | - |
Training of Joseph Lyssikatos
| The College of William & Mary | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| Private companies | 2 |
|---|---|
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
- Stock Market
- Insiders
- Joseph Lyssikatos
